Overview

* Jasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mln

* Company completed $30 mln stock offering, extending cash runway through H1 2026

Outlook

* Company plans to report final conclusions from investigation into BEACON study anomalies in Q4 2025

* Company expects initial data from ETESIAN study in allergic asthma in Q4 2025

* Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026

Result Drivers

* FINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Beat -$1.13 -$1.21

(7

Analysts

)

Q3 Net -$18.70

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Jasper Therapeutics Inc ( JSPR ) is $10.50, about 83% above its November 7 closing price of $1.78

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)